Mumbai: Sun Pharmaceutical Industries Limited has announced the successful completion of its acquisition of Checkpoint ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non ...

MUMBAI, India and PRINCETON, N.J., May 30, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Selvaraju points out that the FDA’s Oncologic Drugs Advisory Committee voted 5-4 against the benefit-risk profile ... UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study ...

Low-cost, low-profit drugs are particularly vulnerable to getting discontinued in the U.S. if Trump does pharmaceutical ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Summit Therapeutics Inc.'s faces FDA hurdles as its HARMONi study shows mixed results on ivonescimab. Click here to find out ...

Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), ...

Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going.